BioSpace News Archive

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has been selected by upcyte® technologies GmbH as the exclusive commercial worldwide distributor of its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).

Select Medical Holdings Corporation (“Select Medical”) (NYSE: SEM), today announced its business outlook for calendar year 2020.

HeartVista, a pioneer in AI-assisted MRI solutions, today announced that entrepreneur and industry veteran Mark Leslie has joined its Board of Directors. Leslie was the co-founder, Chairman and CEO of VERITAS Software.

Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses and inhibits tumor growth when used with its investigational vaccine, ITI-4000, in mice.

AppliedVR, a leading pioneer of therapeutic virtual reality (VR), and S.O.L.V.E. Health Tech, a health equity accelerator embedded within the University of California San Francisco, today announced a collaborative research project to identify barriers and facilitators to digital therapeutics, including VR treatment from AppliedVR, for vulnerable populations such as Medicaid patients

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for GammaTile® Therapy

Electronic Health Records (EHRs), Specialty Hubs and Specialty Pharmacists Can Now Use Technology to Eliminate Weeks of Delays for Patients with Serious and Complex Illnesses

Imricor Medical Systems, Inc. (ASX:IMR) today announces that it has received CE mark approval for its Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode. This follows earlier CE mark approval for Imricor to place its Advantage-MR EP Recorder/Stimulator System on the market in Europe

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has issued approximately 2.24 million shares of its common stock at an average price of approximately $22.32 per share, raising approximately $49.98 million in gross proceeds.

InnerScope continues to launch its premium Hearing Health Products on Waltmart.com with Ear-Ring Relief™ Doctor-Designed & Formulated Dietary Supplement designed to reduce Ringing, Hissing and Buzzing Noises in the Ears for the 60 million Americans that suffer from Tinnitus